IDEXX Laboratories Stock in Brief

By Harris Dyer • Monday, February 03 10:10 • Permanent Link

IDEXX Laboratories logged a 10.8% change during today's morning session, and is now trading at a price of $467.5 per share. The S&P 500 index moved -2.0%. IDXX's trading volume is 390,097 compared to the stock's average volume of 648,858.

IDEXX Laboratories trades -2.18% away from its average analyst target price of $477.93 per share. The 13 analysts following the stock have set target prices ranging from $400.0 to $566.0, and on average have given IDEXX Laboratories a rating of buy.

If you are considering an investment in IDXX, you'll want to know the following:

IDEXX Laboratories's current price is 639.0% above its Graham number of $63.26, which implies that at its current valuation it does not offer a margin of safety
IDEXX Laboratories has moved -26.2% over the last year, and the S&P 500 logged a change of 22.2%
Based on its trailing earnings per share of 10.34, IDEXX Laboratories has a trailing 12 month Price to Earnings (P/E) ratio of 45.2 while the S&P 500 average is 29.3
IDXX has a forward P/E ratio of 39.1 based on its forward 12 month price to earnings (EPS) of $11.96 per share
Its Price to Book (P/B) ratio is 23.7 compared to its sector average of 3.53
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally.
Based in Westbrook, the company has 11,000 full time employees and a market cap of $38.28 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.